Citations (200)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
MarianaS. Gerova & OgnyanI. Petrov. (2014) A Convenient Synthesis of the New Histone Deacetylase Inhibitor Scriptaid. Organic Preparations and Procedures International 46:1, pages 76-79.
Read now
Read now
Na Shao, Jie Zou, Jie Li, Feng Chen, Jianjian Dai, Xun Qu, Xiulian Sun, Daoxin Ma & Chunyan Ji. (2012) Hyper-activation of WNT/β-catenin signaling pathway mediates anti-tumor effects of histone deacetylase inhibitors in acute T lymphoblastic leukemia. Leukemia & Lymphoma 53:9, pages 1769-1778.
Read now
Read now
Ina Oehme, Hedwig E Deubzer, Marco Lodrini, Till Milde & Olaf Witt. (2009) Targeting of HDAC8 and investigational inhibitors in neuroblastoma. Expert Opinion on Investigational Drugs 18:11, pages 1605-1617.
Read now
Read now
Antonello Mai. (2007) The therapeutic uses of chromatin-modifying agents. Expert Opinion on Therapeutic Targets 11:6, pages 835-851.
Read now
Read now
Douglas Marchion & Pamela Münster. (2007) Development of histone deacetylase inhibitors for cancer treatment. Expert Review of Anticancer Therapy 7:4, pages 583-598.
Read now
Read now
Hilmar Weinmann & Eckhard Ottow. (2005) Histone deacetylase inhibitors: a survey of recent patents. Expert Opinion on Therapeutic Patents 15:12, pages 1677-1690.
Read now
Read now
Roberto R Rosato & Steven Grant. (2005) Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opinion on Therapeutic Targets 9:4, pages 809-824.
Read now
Read now
Thomas A Miller. (2004) Patent status of histone deacetylase inhibitors. Expert Opinion on Therapeutic Patents 14:6, pages 791-804.
Read now
Read now
Richard Warburg & Lauren Nguyen. (2004) Inventors and their attorneys must beware of their actions before the US Patent and Trademark Office. Expert Opinion on Therapeutic Patents 14:4, pages 453-456.
Read now
Read now
Roberto R Rosato & Steven Grant. (2004) Histone deacetylase inhibitors in clinical development. Expert Opinion on Investigational Drugs 13:1, pages 21-38.
Read now
Read now
Heehyoung Lee, Natalie Rezai-Zadeh & Edward Seto. (2004) Negative Regulation of Histone Deacetylase 8 Activity by Cyclic AMP-Dependent Protein Kinase A. Molecular and Cellular Biology 24:2, pages 765-773.
Read now
Read now
Thea Kalebic. (2003) Epigenetic transitions: towards therapeutic targets. Expert Opinion on Therapeutic Targets 7:6, pages 693-699.
Read now
Read now
Karl J Tronstad, Kjetil Berge, Rolf Kristian Berge & Øystein Bruserud. (2003) Modified fatty acids and their possible therapeutic targets in malignant diseases. Expert Opinion on Therapeutic Targets 7:5, pages 663-677.
Read now
Read now
Articles from other publishers (187)
Xiaoling Song, Yifan Wu, Xiaojuan Qu & Biao Jiang. (2023) Applications of macrocyclic molecules in cancer therapy: Target cancer development or overcome drug resistance. MedComm – Oncology 2:3.
Crossref
Crossref
Marzieh Ramezani Farani, Maryam Sarlak, Amir Gholami, Maryam Azaraian, Maryam Moradi Binabaj, Sareh Kakavandi, Murtaza M. Tambuwala, Afshin Taheriazam, Mehrdad Hashemi & Sorayya Ghasemi. (2023) Epigenetic drugs as new emerging therapeutics: What is the scale's orientation of application and challenges?. Pathology - Research and Practice 248, pages 154688.
Crossref
Crossref
Georgiana Toma, Eliza Karapetian, Chiara Massa, Dagmar Quandt & Barbara Seliger. (2022) Characterization of the effect of histone deacetylation inhibitors on CD8+ T cells in the context of aging. Journal of Translational Medicine 20:1.
Crossref
Crossref
Asif Raza, Raghuram Kandimalla, Sanjeeb Kalita & Siddhartha Sankar Ghosh. (2022) A Histone Deacetylase Inhibitor Manifests Synergistic Interaction with Artesunate by Suppressing DNA Repair Activity. Sci 4:4, pages 41.
Crossref
Crossref
Chaoqun Huang, Yi Shu, Yueyue Zhu, Hongjing Liu, Xinzhi Wang, Hongmei Wen, Jian Liu & Wei Li. (2022) Discovery of non-substrate, environmentally sensitive turn-on fluorescent probes for imaging HDAC8 in tumor cells and tissue slices. Bioorganic & Medicinal Chemistry 68, pages 116821.
Crossref
Crossref
Nikki M. McCormack, Mahlet B. Abera, Eveline S. Arnold, Rebecca M. Gibbs, Scott E. Martin, Eugen Buehler, Yu-Chi Chen, Lu Chen, Kenneth H. Fischbeck & Barrington G. Burnett. (2021) A high-throughput genome-wide RNAi screen identifies modifiers of survival motor neuron protein. Cell Reports 35:6, pages 109125.
Crossref
Crossref
Desislava V. Stanisheva, Gjorgji Atanasov, Margarita D. Aposstolova & Ognyan I. Petrov. (2021) Design, Synthesis and Biological Activity of New Hydroxamic Acids Containing 2-Imidazolylphenyl(oxy/thio)alkanoic Fragment. Current Bioactive Compounds 17:1, pages 59-66.
Crossref
Crossref
Shuguang Zhang, Xin Tan, Chaogen Liang & Weihua Zhang. (2020)
Design, synthesis, and antifungal evaluation of novel
coumarin‐pyrrole
hybrids
. Journal of Heterocyclic Chemistry 58:2, pages 450-458.
Crossref
Crossref
M. N. Abbas, S. Kausar & H. Cui. (2019) Therapeutic potential of natural products in glioblastoma treatment: targeting key glioblastoma signaling pathways and epigenetic alterations. Clinical and Translational Oncology 22:7, pages 963-977.
Crossref
Crossref
Zachary Pickell, Aaron M. Williams, Hasan B. Alam & Cindy H. Hsu. (2020) Histone Deacetylase Inhibitors: A Novel Strategy for Neuroprotection and Cardioprotection Following Ischemia/Reperfusion Injury. Journal of the American Heart Association 9:11.
Crossref
Crossref
Ettore Crimi, Silvia Cirri, Giuditta Benincasa & Claudio Napoli. (2019) Epigenetics Mechanisms in Multiorgan Dysfunction Syndrome. Anesthesia & Analgesia 129:5, pages 1422-1432.
Crossref
Crossref
Qiuhang Song, Tingting Liu, Yucui Liu, Shuyue Wang, Cong Fan, Lihua Zheng, Yongli Bao, Luguo Sun, Chunlei Yu, Ying Sun, Zhenbo Song, Guannan Wang, Yanxin Huang & Yuxin Li. (2019) An Improved Protocol for the Virtual Screening Discovery of Novel Histone Deacetylase Inhibitors. Chemical and Pharmaceutical Bulletin 67:10, pages 1076-1081.
Crossref
Crossref
Aaron M. Williams, Isabel S. Dennahy, Umar F. Bhatti, Ben E. Biesterveld, Nathan J. Graham, Yongqing Li & Hasan B. Alam. (2019) Histone Deacetylase Inhibitors: A Novel Strategy in Trauma and Sepsis. Shock 52:3, pages 300-306.
Crossref
Crossref
Qiuhang Song, Mingyue Li, Cong Fan, Yucui Liu, Lihua Zheng, Yongli Bao, Luguo Sun, Chunlei Yu, Zhenbo Song, Ying Sun, Guannan Wang, Yanxin Huang & Yuxin Li. (2019) A novel benzamine lead compound of histone deacetylase inhibitor ZINC24469384 can suppresses HepG2 cells proliferation by upregulating NR1H4. Scientific Reports 9:1.
Crossref
Crossref
Mor Dahbash, Ruti Sella, Elinor Megiddo-Barnir, Yael Nisgav, Nataly Tarasenko, Dov Weinberger, Ada Rephaeli & Tami Livnat. (2019) The Histone Deacetylase Inhibitor AN7, Attenuates Choroidal Neovascularization in a Mouse Model. International Journal of Molecular Sciences 20:3, pages 714.
Crossref
Crossref
Maurício Cavicchioli, Aline Zaballa, Queite Paula, Marcela Prieto, Carla Oliveira, Patrizia Civitareale, Maria Ciriolo & Ana Da Costa Ferreira. (2019) Oxidative Assets Toward Biomolecules and Cytotoxicity of New Oxindolimine-Copper(II) and Zinc(II) Complexes. Inorganics 7:2, pages 12.
Crossref
Crossref
Nilanjan Adhikari, Sk Abdul Amin & Tarun Jha. (2018) Selective and nonselective HDAC8 inhibitors: a therapeutic patent review. Pharmaceutical Patent Analyst 7:6, pages 259-276.
Crossref
Crossref
Aline A Zuma & Wanderley de Souza. (2018) Histone deacetylases as targets for antitrypanosomal drugs. Future Science OA 4:8, pages FSO325.
Crossref
Crossref
Shujauddin Ahmad, Ozair Alam, Mohd. Javed Naim, Mohammad Shaquiquzzaman, M. Mumtaz Alam & Muzaffar Iqbal. (2018) Pyrrole: An insight into recent pharmacological advances with structure activity relationship. European Journal of Medicinal Chemistry 157, pages 527-561.
Crossref
Crossref
Eric Salgado, Xuehai Bian, Amber Feng, Hyunsuk Shim & Zhongxing Liang. (2018) HDAC9 overexpression confers invasive and angiogenic potential to triple negative breast cancer cells via modulating microRNA-206. Biochemical and Biophysical Research Communications 503:2, pages 1087-1091.
Crossref
Crossref
Larry Yet. 2018. Privileged Structures in Drug Discovery. Privileged Structures in Drug Discovery
435
480
.
Lori J. Goldstein, Fengmin Zhao, Molin Wang, Ramona F. Swaby, Joseph A. Sparano, Neal J. Meropol, Kapil N. Bhalla, Christine M. Pellegrino, R. Katherine Alpaugh, Carla I. Falkson, Paula Klein & George W. Sledge. (2017) A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104). Breast Cancer Research and Treatment 165:2, pages 375-382.
Crossref
Crossref
Subhasish Tapadar, Shaghayegh Fathi, Idris Raji, Wilson Omesiete, James R. Kornacki, Sandra C. Mwakwari, Masanori Miyata, Kazunori Mitsutake, Jian-Dong Li, Milan Mrksich & Adegboyega K. Oyelere. (2015) A structure–activity relationship of non-peptide macrocyclic histone deacetylase inhibitors and their anti-proliferative and anti-inflammatory activities. Bioorganic & Medicinal Chemistry 23:24, pages 7543-7564.
Crossref
Crossref
Ihab Halaweish, Vahagn Nikolian, Patrick Georgoff, Yongqing Li & Hasan B. Alam. (2015) Creating a “Prosurvival Phenotype” Through Histone Deacetylase Inhibition. Shock 44:Supplement 1, pages 6-16.
Crossref
Crossref
Satya P. Gupta. (2015) QSAR Studies on Hydroxamic Acids: A Fascinating Family of Chemicals with a Wide Spectrum of Activities. Chemical Reviews 115:13, pages 6427-6490.
Crossref
Crossref
Young Ho Seo. (2015) Dual Inhibitors Against Topoisomerases and Histone Deacetylases. Journal of Cancer Prevention 20:2, pages 85-91.
Crossref
Crossref
Adile Ayati, Saeed Emami, Ali Asadipour, Abbas Shafiee & Alireza Foroumadi. (2015) Recent applications of 1,3-thiazole core structure in the identification of new lead compounds and drug discovery. European Journal of Medicinal Chemistry 97, pages 699-718.
Crossref
Crossref
K.M. Lawrence, T.R. Jackson, D. Jamieson, A. Stevens, G. Owens, B.S. Sayan, I.C. Locke & P.A. Townsend. (2015) Urocortin – From Parkinson's disease to the skeleton. The International Journal of Biochemistry & Cell Biology 60, pages 130-138.
Crossref
Crossref
Xing-dong Xu, Lan Yang, Li-yun Zheng, Yan-yan Pan, Zhi-fei Cao, Zhi-qing Zhang, Quan-sheng Zhou, Bo Yang & Cong Cao. (2014) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells. BMC Cancer 14:1.
Crossref
Crossref
Lan-Lan Zang, Xue-Jiao Wang, Xiao-Bo Li, Shu-Qing Wang, Wei-Ren Xu, Xian-Bin Xie, Xian-Chao Cheng, Huan Ma & Run-Ling Wang. (2014) SAHA-based novel HDAC inhibitor design by core hopping method. Journal of Molecular Graphics and Modelling 54, pages 10-18.
Crossref
Crossref
Murugavel Ponnusamy, Xiaoxu Zhou, Yanli Yan, Jinhua Tang, Evelyn Tolbert, Ting C. Zhao, Rujun Gong & Shougang Zhuang. (2014) Blocking Sirtuin 1 and 2 Inhibits Renal Interstitial Fibroblast Activation and Attenuates Renal Interstitial Fibrosis in Obstructive Nephropathy. Journal of Pharmacology and Experimental Therapeutics 350:2, pages 243-256.
Crossref
Crossref
N. B. Haas, I. Quirt, S. Hotte, E. McWhirter, R. Polintan, S. Litwin, P. D. Adams, T. McBryan, L. Wang, L. P. Martin, M. vonMehren, R. K. Alpaugh, J. Zweibel & A. Oza. (2014) Phase II trial of vorinostat in advanced melanoma. Investigational New Drugs 32:3, pages 526-534.
Crossref
Crossref
Subha Kalyaanamoorthy & Yi-Ping Phoebe Chen. (2014) A steered molecular dynamics mediated hit discovery for histone deacetylases. Physical Chemistry Chemical Physics 16:8, pages 3777.
Crossref
Crossref
Sascha Venturelli, Alexander Berger, Alexander Böcker, Christian Busch, Timo Weiland, Seema Noor, Christian Leischner, Sabine Schleicher, Mascha Mayer, Thomas S. Weiss, Stephan C. Bischoff, Ulrich M. Lauer & Michael Bitzer. (2013) Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells. PLoS ONE 8:8, pages e73097.
Crossref
Crossref
R Soldi, A L Cohen, L Cheng, Y Sun, P J Moos & A H Bild. (2011) A genomic approach to predict synergistic combinations for breast cancer treatment. The Pharmacogenomics Journal 13:1, pages 94-104.
Crossref
Crossref
Sung-Koo Kim, Hong Yang, Juan M. Pascual & Darryl C. De Vivo. (2012) Valproic Acid Enhances Glucose Transport in the Cultured Brain Astrocytes of Glucose Transporter 1 Heterozygous Mice. Journal of Child Neurology 28:1, pages 70-76.
Crossref
Crossref
Jin Boo Jeong & Seong-Ho Lee. (2013) Protocatechualdehyde possesses anti-cancer activity through downregulating cyclin D1 and HDAC2 in human colorectal cancer cells. Biochemical and Biophysical Research Communications 430:1, pages 381-386.
Crossref
Crossref
C.J. Marmion, J.P. Parker & K.B. Nolan. 2013. Comprehensive Inorganic Chemistry II. Comprehensive Inorganic Chemistry II
683
708
.
Vaishali M. Patil & Satya P. Gupta. 2013. Hydroxamic Acids. Hydroxamic Acids
71
98
.
Satya P. Gupta & Anjana Sharma. 2013. Hydroxamic Acids. Hydroxamic Acids
1
17
.
Julie A. Pollock, Michelle D. Larrea, Jeff S. Jasper, Donald P. McDonnell & Dewey G. McCafferty. (2012) Lysine-Specific Histone Demethylase 1 Inhibitors Control Breast Cancer Proliferation in ERα-Dependent and -Independent Manners. ACS Chemical Biology 7:7, pages 1221-1231.
Crossref
Crossref
Nina Reichert, Mohamed-Amin Choukrallah & Patrick Matthias. (2012) Multiple roles of class I HDACs in proliferation, differentiation, and development. Cellular and Molecular Life Sciences 69:13, pages 2173-2187.
Crossref
Crossref
Syam B. Nair, Mahesh Kumar Teli, H. Pradeep & G.K. Rajanikant. (2012) Computational identification of novel histone deacetylase inhibitors by docking based QSAR. Computers in Biology and Medicine 42:6, pages 697-705.
Crossref
Crossref
Eun-Taex Oh, Moon-Taek Park, Bo-Hwa Choi, Seonggu Ro, Eun-Kyung Choi, Seong-Yun Jeong & Heon Joo Park. (2010) Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells. Investigational New Drugs 30:2, pages 435-442.
Crossref
Crossref
William Guerrant, Vishal Patil, Joshua C. Canzoneri & Adegboyega K. Oyelere. (2012) Dual Targeting of Histone Deacetylase and Topoisomerase II with Novel Bifunctional Inhibitors. Journal of Medicinal Chemistry 55:4, pages 1465-1477.
Crossref
Crossref
Bryan J. Schneider, Gregory P. Kalemkerian, Deborah Bradley, David C. Smith, Merrill J. Egorin, Stephanie Daignault, Rodney Dunn & Maha Hussain. (2010) Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Investigational New Drugs 30:1, pages 249-257.
Crossref
Crossref
John K. Wiencke. 2012. Patho-Epigenetics of Disease. Patho-Epigenetics of Disease
71
90
.
Sang-Hyun Song, Sae-Won Han & Yung-Jue Bang. (2011) Epigenetic-Based Therapies in Cancer. Drugs 71:18, pages 2391-2403.
Crossref
Crossref
Julie E. Chang & Brad S. Kahl. (2011) Current Status of Targeted Therapies for Mantle Cell Lymphoma. Drugs 71:17, pages 2307-2326.
Crossref
Crossref
Eva Also-Rallo, Laura Alías, Rebeca Martínez-Hernández, Lidia Caselles, María J Barceló, Montserrat Baiget, Sara Bernal & Eduardo F Tizzano. (2011) Treatment of spinal muscular atrophy cells with drugs that upregulate SMN expression reveals inter- and intra-patient variability. European Journal of Human Genetics 19:10, pages 1059-1065.
Crossref
Crossref
Wenxin Gu & Richard B. Silverman. (2011) Synthesis of (S)-2-Boc-Amino-8-(R)-(tert-butyldimethylsilanyloxy)decanoic acid, a precursor to the unusual amino acid residue of the anticancer agent microsporin B. Tetrahedron Letters 52:42, pages 5438-5440.
Crossref
Crossref
Juncheng Cui, Wanchun Wang, Zhihong Li, Zhaogui Zhang, Bei Wu & Li Zeng. (2011) Epigenetic changes in osteosarcoma. Bulletin du Cancer 98:7, pages E62-E68.
Crossref
Crossref
Sanjeev Banerjee, Dejuan Kong, Zhiwei Wang, Bin Bao, Gilda G. Hillman & Fazlul H. Sarkar. (2011) Attenuation of multi-targeted proliferation-linked signaling by 3,3′-diindolylmethane (DIM): From bench to clinic. Mutation Research/Reviews in Mutation Research 728:1-2, pages 47-66.
Crossref
Crossref
Z. V. Chitikova, N. D. Aksenov, V. A. Pospelov & T. V. Pospelova. (2011) Sodium butyrate induces cell senescence in transformed rodent cells resistant to apoptosis. Cell and Tissue Biology 5:3, pages 235-242.
Crossref
Crossref
K Ted Thurn, Scott Thomas, Amy Moore & Pamela N Munster. (2011) Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncology 7:2, pages 263-283.
Crossref
Crossref
Li-Jeen Mah, Christian Orlowski, Katherine Ververis, Raja S Vasireddy, Assam El-Osta & Tom C Karagiannis. (2011) Evaluation of the efficacy of radiation-modifying compounds using γH2AX as a molecular marker of DNA double-strand breaks. Genome Integrity 2.
Crossref
Crossref
Chittari Pabba, Brian T. Gregg, Douglas B. Kitchen, Zhen Jia Chen & Angela Judkins. (2011) Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Bioorganic & Medicinal Chemistry Letters 21:1, pages 324-328.
Crossref
Crossref
Isamu Hoshino & Hisahiro Matsubara. (2010) Recent advances in histone deacetylase targeted cancer therapy. Surgery Today 40:9, pages 809-815.
Crossref
Crossref
Nighat Noureen, Hamid Rashid & Saima Kalsoom. (2010) Identification of type-specific anticancer histone deacetylase inhibitors: road to success. Cancer Chemotherapy and Pharmacology 66:4, pages 625-633.
Crossref
Crossref
Sandra C. Mwakwari, William Guerrant, Vishal Patil, Shabana I. Khan, Babu L. Tekwani, Zachary A. Gurard-Levin, Milan Mrksich & Adegboyega K. Oyelere. (2010) Non-Peptide Macrocyclic Histone Deacetylase Inhibitors Derived from Tricyclic Ketolide Skeleton. Journal of Medicinal Chemistry 53:16, pages 6100-6111.
Crossref
Crossref
William Guerrant, Sandra C. Mwakwari, Po C. Chen, Shabana I. Khan, Babu L. Tekwani & Adegboyega K. Oyelere. (2010) A Structure-Activity Relationship Study of the Antimalarial and Antileishmanial Activities of Nonpeptide Macrocyclic Histone Deacetylase Inhibitors. ChemMedChem 5:8, pages 1232-1235.
Crossref
Crossref
Gema Alcarraz-Vizán, Joan Boren, Wai-Nang Paul Lee & Marta Cascante. (2010) Histone deacetylase inhibition results in a common metabolic profile associated with HT29 differentiation. Metabolomics 6:2, pages 229-237.
Crossref
Crossref
A. Iglesias-Linares, R.M. Yañez-Vico & M.A. González-Moles. (2010) Potential role of HDAC inhibitors in cancer therapy: Insights into oral squamous cell carcinoma. Oral Oncology 46:5, pages 323-329.
Crossref
Crossref
Christopher J. Hoimes & W. Kevin Kelly. (2009) Redefining hormone resistance in prostate cancer. Therapeutic Advances in Medical Oncology 2:2, pages 107-123.
Crossref
Crossref
Takashi Watanabe, Harumi Kato, Yukio Kobayashi, Satoshi Yamasaki, Yuriko Morita‐Hoshi, Hiroki Yokoyama, Yasuo Morishima, Justin L. Ricker, Tetsuya Otsuki, Akiko Miyagi‐Maesima, Yoshihiro Matsuno & Kensei Tobinai. (2009) Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Science 101:1, pages 196-200.
Crossref
Crossref
Neeraj Agarwal & Maha Hussain. (2009) Management of Bladder Cancer. Drugs 69:9, pages 1173-1187.
Crossref
Crossref
Joice Kuroiwa‐Trzmielina, Aline de Conti, Clarissa Scolastici, Douglas Pereira, Maria Aderuza Horst, Eduardo Purgatto, Thomas Prates Ong & Fernando Salvador Moreno. (2009) Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: Efficacy of tributyrin, a butyric acid prodrug. International Journal of Cancer 124:11, pages 2520-2527.
Crossref
Crossref
Guoling Ren, Guocui Zhang, Zhixiong Dong, Zhiwei Liu, Lin Li, Yunpeng Feng, Dongmei Su, Yu Zhang, Baiqu Huang & Jun Lu. (2009) Recruitment of HDAC4 by transcription factor YY1 represses HOXB13 to affect cell growth in AR-negative prostate cancers. The International Journal of Biochemistry & Cell Biology 41:5, pages 1094-1101.
Crossref
Crossref
Takuya Kato, Yohei Shimono, Masaki Hasegawa, Mayumi Jijiwa, Atsushi Enomoto, Naoya Asai, Yoshiki Murakumo & Masahide Takahashi. (2009) Characterization of the HDAC1 Complex That Regulates the Sensitivity of Cancer Cells to Oxidative Stress. Cancer Research 69:8, pages 3597-3604.
Crossref
Crossref
Ken Shiozawa, Takeo Nakanishi, Ming Tan, Hong-Bin Fang, Wen-chyi Wang, Martin J. Edelman, David Carlton, Ivana Gojo, Edward A. Sausville & Douglas D. Ross. (2009) Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias. Clinical Cancer Research 15:5, pages 1698-1707.
Crossref
Crossref
Didem Dayangaç-Erden, Gamze Bora, Peruze Ayhan, Çetin Kocaefe, Sevim Dalkara, Kemal Yelekçi, Ayhan S. Demir & Hayat Erdem-Yurter. (2009)
Histone Deacetylase Inhibition Activity and Molecular Docking of (
E
)-Resveratrol: Its Therapeutic Potential in Spinal Muscular Atrophy
. Chemical Biology & Drug Design 73:3, pages 355-364.
Crossref
Crossref
Margaret T. Kasner & Selina M. Luger. (2009) Update on the therapy for myelodysplastic syndrome. American Journal of Hematology 84:3, pages 177-186.
Crossref
Crossref
Adegboyega K. Oyelere, Po C. Chen, William Guerrant, Sandra C. Mwakwari, Rebecca Hood, Yunzhe Zhang & Yuhong Fan. (2008) Non-Peptide Macrocyclic Histone Deacetylase Inhibitors. Journal of Medicinal Chemistry 52:2, pages 456-468.
Crossref
Crossref
Ina Oehme, Hedwig E. Deubzer, Dennis Wegener, Diana Pickert, Jan-Peter Linke, Barbara Hero, Annette Kopp-Schneider, Frank Westermann, Scott M. Ulrich, Andreas von Deimling, Matthias Fischer & Olaf Witt. (2009) Histone Deacetylase 8 in Neuroblastoma Tumorigenesis. Clinical Cancer Research 15:1, pages 91-99.
Crossref
Crossref
Lei Fang & Sam T. Hwang. 2009. Chemokine Receptors in Cancer. Chemokine Receptors in Cancer
93
108
.
Jose A. Karam & Jer-Tsong Hsieh. 2009. Apoptosis in Carcinogenesis and Chemotherapy. Apoptosis in Carcinogenesis and Chemotherapy
25
50
.
Elizabeth A. Thomas, Giovanni Coppola, Paula A. Desplats, Bin Tang, Elisabetta Soragni, Ryan Burnett, Fuying Gao, Kelsey M. Fitzgerald, Jenna F. Borok, David Herman, Daniel H. Geschwind & Joel M. Gottesfeld. (2008) The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proceedings of the National Academy of Sciences 105:40, pages 15564-15569.
Crossref
Crossref
George Lipkin. (2008) Plasticity of the Cancer Cell: Implications for Epigenetic Control of Melanoma and Other Malignancies. Journal of Investigative Dermatology 128:9, pages 2152-2155.
Crossref
Crossref
S. Gelmini, M. Mangoni, M. Serio, P. Romagnani & E. Lazzeri. (2014) The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis. Journal of Endocrinological Investigation 31:9, pages 809-819.
Crossref
Crossref
Andrea Newbold, Ralph K. Lindemann, Leonie A. Cluse, Kate F. Whitecross, Anthony E. Dear & Ricky W. Johnstone. (2008) Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. Molecular Cancer Therapeutics 7:5, pages 1066-1079.
Crossref
Crossref
Denis Mottet & Vincent Castronovo. (2007) Histone deacetylases: target enzymes for cancer therapy. Clinical & Experimental Metastasis 25:2, pages 183-189.
Crossref
Crossref
Sung-Keum Seo, Hyeon-Ok Jin, Hyung-Chahn Lee, Sang-Hyeok Woo, Eun-Sung Kim, Doo-Hyun Yoo, Su-Jae Lee, Sungkwan An, Chang-Hun Rhee, Seok-Il Hong, Tae-Boo Choe & In-Chul Park. (2008) Combined Effects of Sulindac and Suberoylanilide Hydroxamic Acid on Apoptosis Induction in Human Lung Cancer Cells. Molecular Pharmacology 73:3, pages 1005-1012.
Crossref
Crossref
Vinodhkumar Radhakrishnan, Young-Sun Song & Devaki Thiruvengadam. (2008) Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. Biomedicine & Pharmacotherapy 62:2, pages 85-93.
Crossref
Crossref
Colleen C. Spurling, Cassandra A. Godman, Emily J. Noonan, Theodore P. Rasmussen, Daniel W. Rosenberg & Charles Giardina. (2008) HDAC3 overexpression and colon cancer cell proliferation and differentiation. Molecular Carcinogenesis 47:2, pages 137-147.
Crossref
Crossref
Elizabeth A. Griffiths & Steven D. Gore. (2008) DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes. Seminars in Hematology 45:1, pages 23-30.
Crossref
Crossref
Roberto R. Rosato & Steven Grant. 2008. Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy. Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy
115
131
.
Sai Murali Krishna Pulukuri, Bharathi Gorantla & Jasti S. Rao. (2007) Inhibition of Histone Deacetylase Activity Promotes Invasion of Human Cancer Cells through Activation of Urokinase Plasminogen Activator. Journal of Biological Chemistry 282:49, pages 35594-35603.
Crossref
Crossref
Sampath-Kumar Anandan, John S. Ward, Richard D. Brokx, Trisha Denny, Mark R. Bray, Dinesh V. Patel & Xiao-Yi Xiao. (2007) Design and synthesis of thiazole-5-hydroxamic acids as novel histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters 17:21, pages 5995-5999.
Crossref
Crossref
Christopher L. Hamblett, Joey L. Methot, Dawn M. Mampreian, David L. Sloman, Matthew G. Stanton, Astrid M. Kral, Judith C. Fleming, Jonathan C. Cruz, Melissa Chenard, Nicole Ozerova, Anna M. Hitz, Hongmei Wang, Sujal V. Deshmukh, Naim Nazef, Andreas Harsch, Bethany Hughes, William K. Dahlberg, Alex A. Szewczak, Richard E. Middleton, Ralph T. Mosley, J. Paul Secrist & Thomas A. Miller. (2007) The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters 17:19, pages 5300-5309.
Crossref
Crossref
Thomas Beckers, Carmen Burkhardt, Heike Wieland, Petra Gimmnich, Thomas Ciossek, Thomas Maier & Karl Sanders. (2007) Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. International Journal of Cancer 121:5, pages 1138-1148.
Crossref
Crossref
S C Hodawadekar & R Marmorstein. (2007) Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design. Oncogene 26:37, pages 5528-5540.
Crossref
Crossref
Takashi Kumagai, Naoki Wakimoto, Dong Yin, Sigal Gery, Norihiko Kawamata, Noriyuki Takai, Naoki Komatsu, Alexy Chumakov, Yasufumi Imai & H.Phillip Koeffler. (2007) Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. International Journal of Cancer 121:3, pages 656-665.
Crossref
Crossref
Wenxin Gu, Mercedes Cueto, Paul R. Jensen, William Fenical & Richard B. Silverman. (2007) Microsporins A and B: new histone deacetylase inhibitors from the marine-derived fungus Microsporum cf. gypseum and the solid-phase synthesis of microsporin A. Tetrahedron 63:28, pages 6535-6541.
Crossref
Crossref
Sandro Belvedere, David J. Witter, Jiaming Yan, J. Paul Secrist, Victoria Richon & Thomas A. Miller. (2007) Aminosuberoyl hydroxamic acids (ASHAs): A potent new class of HDAC inhibitors. Bioorganic & Medicinal Chemistry Letters 17:14, pages 3969-3971.
Crossref
Crossref
Antonello Mai, Sergio Valente, Dante Rotili, Silvio Massa, Giorgia Botta, Gerald Brosch, Marco Miceli, Angela Nebbioso & Lucia Altucci. (2007) Novel pyrrole-containing histone deacetylase inhibitors endowed with cytodifferentiation activity. The International Journal of Biochemistry & Cell Biology 39:7-8, pages 1510-1522.
Crossref
Crossref
Tom Lin, Huazhen Chen, Elena Koustova, Elizabeth A. Sailhamer, Yongqing Li, Christian Shults, Baoling Liu, Peter Rhee, John Kirkpatrick & Hasan B. Alam. (2007) Histone deacetylase as therapeutic target in a rodent model of hemorrhagic shock: Effect of different resuscitation strategies on lung and liver. Surgery 141:6, pages 784-794.
Crossref
Crossref
Daniel Riester, Christian Hildmann & Andreas Schwienhorst. (2007) Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases. Applied Microbiology and Biotechnology 75:3, pages 499-514.
Crossref
Crossref
Lina Pan, Jun Lu, Xiuli Wang, Liping Han, Yu Zhang, Songyan Han & Baiqu Huang. (2007) Histone deacetylase inhibitor trichostatin a potentiates doxorubicin‐induced apoptosis by up‐regulating PTEN expression. Cancer 109:8, pages 1676-1688.
Crossref
Crossref
Amy L. Cooper, Victoria L. Greenberg, Pamela S. Lancaster, John R. van NagellJr.Jr., Stephen G. Zimmer & Susan C. Modesitt. (2007) In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. Gynecologic Oncology 104:3, pages 596-601.
Crossref
Crossref
Antonello Mai, Dante Rotili, Silvio Massa, Gerald Brosch, Giovanna Simonetti, Claudio Passariello & Anna Teresa Palamara. (2007) Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans. Bioorganic & Medicinal Chemistry Letters 17:5, pages 1221-1225.
Crossref
Crossref
Jana Vlasáková, Zora Nováková, Lenka Rossmeislová, Michal Kahle, Pavel Hozák & Zdenĕk Hodný. (2006) Histone deacetylase inhibitors suppress IFNα-induced up-regulation of promyelocytic leukemia protein. Blood 109:4, pages 1373-1380.
Crossref
Crossref
James E. Johnson, Carol Carvallo, Debra D. Dolliver, Natalia Sanchez, Vilma Garza, Diana C. Canseco, Gordon L. Eggleton & Frank R. Fronczek. (2007) Bisamidoximes: Synthesis and Complexation with Iron(III). Australian Journal of Chemistry 60:9, pages 685.
Crossref
Crossref
Beatrix M. Ueberheide & Sahana Mollah. (2007) Deciphering the histone code using mass spectrometry. International Journal of Mass Spectrometry 259:1-3, pages 46-56.
Crossref
Crossref
H. Weinmann & E. Ottow. 2007. Comprehensive Medicinal Chemistry II. Comprehensive Medicinal Chemistry II
221
251
.
Owen A. O’Connor & Paul Hamlin. (2006) New Drugs for the Treatment of Advanced-Stage Diffuse Large Cell Lymphomas. Seminars in Hematology 43:4, pages 251-261.
Crossref
Crossref
Antonello MaiSilvio MassaDante RotiliSilvia SimeoniRino RagnoGiorgia BottaAngela NebbiosoMarco MiceliLucia AltucciGerald Brosch. (2006) Synthesis and Biological Properties of Novel, Uracil-Containing Histone Deacetylase Inhibitors. Journal of Medicinal Chemistry 49:20, pages 6046-6056.
Crossref
Crossref
Thomas B. Tomasi, William J. Magner & A. Nazmul H. Khan. (2006) Epigenetic regulation of immune escape genes in cancer. Cancer Immunology, Immunotherapy 55:10, pages 1159-1184.
Crossref
Crossref
Xiangwei Huang & Bin Guo. (2006) Adenomatous Polyposis Coli Determines Sensitivity to Histone Deacetylase Inhibitor–Induced Apoptosis in Colon Cancer Cells. Cancer Research 66:18, pages 9245-9251.
Crossref
Crossref
Jessica E. Bolden, Melissa J. Peart & Ricky W. Johnstone. (2006) Anticancer activities of histone deacetylase inhibitors. Nature Reviews Drug Discovery 5:9, pages 769-784.
Crossref
Crossref
Anupama Munshi, Toshimitsu Tanaka, Marvette L. Hobbs, Susan L. Tucker, Victoria M. Richon & Raymond E. Meyn. (2006) Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of γ-H2AX foci. Molecular Cancer Therapeutics 5:8, pages 1967-1974.
Crossref
Crossref
Hans Christian Beck, Eva C. Nielsen, Rune Matthiesen, Lars H. Jensen, Maxwell Sehested, Paul Finn, Morten Grauslund, Anne Maria Hansen & Ole Nørregaard Jensen. (2006) Quantitative Proteomic Analysis of Post-translational Modifications of Human Histones. Molecular & Cellular Proteomics 5:7, pages 1314-1325.
Crossref
Crossref
David G. Fatkins, Andrew D. Monnot & Weiping Zheng. (2006) Nε-Thioacetyl-lysine: A multi-facet functional probe for enzymatic protein lysine Nε-deacetylation. Bioorganic & Medicinal Chemistry Letters 16:14, pages 3651-3656.
Crossref
Crossref
T C Karagiannis & A El-Osta. (2006) Modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene 25:28, pages 3885-3893.
Crossref
Crossref
Kathleen W. Beekman & Maha Hussain. (2006) Targeted approaches for the management of metastatic prostate cancer. Current Oncology Reports 8:3, pages 206-212.
Crossref
Crossref
Zhengwang Zhang, Jose Karam, Eugene Frenkel, Arthur Sagalowsky & Jer-Tsong Hsieh. (2006) The application of epigenetic modifiers on the treatment of prostate and bladder cancer. Urologic Oncology: Seminars and Original Investigations 24:2, pages 152-160.
Crossref
Crossref
Tom Lin, Hasan B. Alam, Huazhen Chen, Joy Britten-Webb, Peter Rhee, John Kirkpatrick & Elena Koustova. (2006) Cardiac histones are substrates of histone deacetylase activity in hemorrhagic shock and resuscitation. Surgery 139:3, pages 365-376.
Crossref
Crossref
Oliver H. Krämer, Daniela Baus, Shirley K. Knauer, Stefan Stein, Elke Jäger, Roland H. Stauber, Manuel Grez, Edith Pfitzner & Thorsten Heinzel. (2006) Acetylation of Stat1 modulates NF-κB activity. Genes & Development 20:4, pages 473-485.
Crossref
Crossref
Antonello Mai, Silvio Massa, Sergio Valente, Silvia Simeoni, Rino Ragno, Patrizia Bottoni, Roberto Scatena & Gerald Brosch. (2006) Aroyl-Pyrrolyl Hydroxyamides: Influence of Pyrrole C4-Phenylacetyl Substitution on Histone Deacetylase Inhibition. ChemMedChem 1:2, pages 225-237.
Crossref
Crossref
Norihiro Sato, Noriyoshi Fukushima, Rubens Chang, Hiroyuki Matsubayashi & Michael Goggins. (2006) Differential and Epigenetic Gene Expression Profiling Identifies Frequent Disruption of the RELN Pathway in Pancreatic Cancers. Gastroenterology 130:2, pages 548-565.
Crossref
Crossref
Dominique Meunier & Christian Seiser. 2006. Histone Deacetylases. Histone Deacetylases
3
22
.
Dhanshri C. Juvale, Vishal V. Kulkarni, Hemantkumar S. Deokar, Nilesh K. Wagh, Subhash B. Padhye & Vithal M. Kulkarni. (2006) 3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues. Organic & Biomolecular Chemistry 4:15, pages 2858.
Crossref
Crossref
JOHN K. BUOLAMWINI. 2006. Novel Anticancer Agents. Novel Anticancer Agents
1
35
.
S. Rottmann & B. Lüscher. 2006. The Myc/Max/Mad Transcription Factor Network. The Myc/Max/Mad Transcription Factor Network
63
122
.
Daniela CecconiMassimo DonadelliAldo ScarpaAlberto MilliMarta PalmieriMahmoud HamdanLiliana B. ArecesJuri RappsilberPier Giorgio Righetti. (2005) Proteomic Analysis of Pancreatic Ductal Carcinoma Cells after Combined Treatment with Gemcitabine and Trichostatin A. Journal of Proteome Research 4:6, pages 1909-1916.
Crossref
Crossref
Antonello Mai, Silvio Massa, Dante Rotili, Riccardo Pezzi, Patrizia Bottoni, Roberto Scatena, Joachim Meraner & Gerald Brosch. (2005) Exploring the connection unit in the HDAC inhibitor pharmacophore model: Novel uracil-based hydroxamates. Bioorganic & Medicinal Chemistry Letters 15:21, pages 4656-4661.
Crossref
Crossref
C A Bradbury, F L Khanim, R Hayden, C M Bunce, D A White, M T Drayson, C Craddock & B M Turner. (2005) Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 19:10, pages 1751-1759.
Crossref
Crossref
Nicholas A. Di Prospero & Kenneth H. Fischbeck. (2005) Therapeutics development for triplet repeat expansion diseases. Nature Reviews Genetics 6:10, pages 756-766.
Crossref
Crossref
Riku Sakimura, Kazuhiro Tanaka, Fumihiko Nakatani, Tomoya Matsunobu, Xu Li, Masuo Hanada, Takamitsu Okada, Tomoyuki Nakamura, Yoshihiro Matsumoto & Yukihide Iwamoto. (2005) Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors. International Journal of Cancer 116:5, pages 784-792.
Crossref
Crossref
Owen A. O'Connor. (2005) Targeting Histones and Proteasomes: New Strategies for the Treatment of Lymphoma. Journal of Clinical Oncology 23:26, pages 6429-6436.
Crossref
Crossref
Rebecca Kristeleit, Peter Fong, G. Wynne Aherne & Johann de Bono. (2005) Histone Deacetylase Inhibitors: Emerging Anticancer Therapeutic Agents?. Clinical Lung Cancer 7, pages S19-S30.
Crossref
Crossref
Steven A. Belinsky. (2005) Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis 26:9, pages 1481-1487.
Crossref
Crossref
Stefan Schäfer & Manfred Jung. (2005) Chromatin Modifications as Targets for New Anticancer Drugs. Archiv der Pharmazie 338:8, pages 347-357.
Crossref
Crossref
Jill Jarecki, Xiaocun Chen, Alexandra Bernardino, Daniel D. Coovert, Michael Whitney, Arthur Burghes, Jeffrey Stack & Brian A. Pollok. (2005) Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Human Molecular Genetics 14:14, pages 2003-2018.
Crossref
Crossref
Lihong Du, Donald G. Musson & Amy Qiu Wang. (2005) High turbulence liquid chromatography online extraction and tandem mass spectrometry for the simultaneous determination of suberoylanilide hydroxamic acid and its two metabolites in human serum. Rapid Communications in Mass Spectrometry 19:13, pages 1779-1787.
Crossref
Crossref
Allison R Jilbert & Stephen A Locarnini. 2005. Viral Hepatitis. Viral Hepatitis
193
209
.
Anupama Munshi, John F. Kurland, Takashi Nishikawa, Toshimitsu Tanaka, Marvette L. Hobbs, Susan L. Tucker, Sheikh Ismail, Craig Stevens & Raymond E. Meyn. (2005) Histone Deacetylase Inhibitors Radiosensitize Human Melanoma Cells by Suppressing DNA Repair Activity. Clinical Cancer Research 11:13, pages 4912-4922.
Crossref
Crossref
Owen A. O'Connor. (2005) Developing new drugs for the treatment of lymphoma. European Journal of Haematology 75, pages 150-158.
Crossref
Crossref
Patrick Angibaud, Janine Arts, Kristof Van Emelen, Virginie Poncelet, Isabelle Pilatte, Bruno Roux, Sven Van Brandt, Marc Verdonck, Hans De Winter, Peter Ten Holte, Ann Marien, Wim Floren, Boudewijn Janssens, Jacky Van Dun, An Aerts, Jacky Van Gompel, Sandrine Gaurrand, Laurence Queguiner, Jean-Michel Argoullon, Luc Van Hijfte, Eddy Freyne & Michel Janicot. (2005) Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors. European Journal of Medicinal Chemistry 40:6, pages 597-606.
Crossref
Crossref
Tatsuo Ito, Mamoru Ouchida, Yuki Morimoto, Aki Yoshida, Yoshimi Jitsumori, Toshifumi Ozaki, Hiroshi Sonobe, Hajime Inoue & Kenji Shimizu. (2005) Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. Cancer Letters 224:2, pages 311-319.
Crossref
Crossref
Markus Biel, Veit Wascholowski & Athanassios Giannis. (2005) Epigenetics—An Epicenter of Gene Regulation: Histones and Histone‐Modifying Enzymes. Angewandte Chemie International Edition 44:21, pages 3186-3216.
Crossref
Crossref
Markus Biel, Veit Wascholowski & Athanassios Giannis. (2005) Epigenetik – ein Epizentrum der Genregulation: Histone und histonmodifizierende Enzyme. Angewandte Chemie 117:21, pages 3248-3280.
Crossref
Crossref
Antonello MaiSilvio MassaRiccardo PezziSilvia SimeoniDante RotiliAngela NebbiosoAnnamaria ScognamiglioLucia AltucciPeter LoidlGerald Brosch. (2005) Class II (IIa)-Selective Histone Deacetylase Inhibitors. 1. Synthesis and Biological Evaluation of Novel (Aryloxopropenyl)pyrrolyl Hydroxyamides. Journal of Medicinal Chemistry 48:9, pages 3344-3353.
Crossref
Crossref
Kevin Camphausen, David Cerna, Tamalee Scott, Mary Sproull, William E. Burgan, Michael A. Cerra, Howard Fine & Philip J. Tofilon. (2004)
Enhancement of
in vitro
and
in vivo
tumor cell radiosensitivity by valproic acid
. International Journal of Cancer 114:3, pages 380-386.
Crossref
Crossref
Xiaohong Zhang, Yukiyasu Ozawa, Heehyoung Lee, Yu-Der Wen, Tse-Hua Tan, Brian E. Wadzinski & Edward Seto. (2005) Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4. Genes & Development 19:7, pages 827-839.
Crossref
Crossref
Sampath-Kumar Anandan, John S. Ward, Richard D. Brokx, Mark R. Bray, Dinesh V. Patel & Xiao-Xi Xiao. (2005) Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters 15:8, pages 1969-1972.
Crossref
Crossref
Nigel P. Mongan & Lorraine J. Gudas. (2005)
Valproic acid, in combination with all-
trans
retinoic acid and 5-aza-2′-deoxycytidine, restores expression of silenced
RARβ2
in breast cancer cells
. Molecular Cancer Therapeutics 4:3, pages 477-486.
Crossref
Crossref
Takuji Mori, Joseph Kim, Tomoki Yamano, Hiroya Takeuchi, Sharon Huang, Naoyuki Umetani, Kazuo Koyanagi & Dave S.B. Hoon. (2005) Epigenetic Up-regulation of C-C Chemokine Receptor 7 and C-X-C Chemokine Receptor 4 Expression in Melanoma Cells. Cancer Research 65:5, pages 1800-1807.
Crossref
Crossref
Jing Hu & Nancy H. Colburn. (2005) Histone Deacetylase Inhibition Down-Regulates Cyclin D1 Transcription by Inhibiting Nuclear Factor-κB/p65 DNA Binding. Molecular Cancer Research 3:2, pages 100-109.
Crossref
Crossref
J. S. Ungerstedt, Y. Sowa, W.-S. Xu, Y. Shao, M. Dokmanovic, G. Perez, L. Ngo, A. Holmgren, X. Jiang & P. A. Marks. (2005) Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proceedings of the National Academy of Sciences 102:3, pages 673-678.
Crossref
Crossref
Ian M. AdcockBorja CosioLoukia TsaprouniPeter J. BarnesKazuhiro Ito. (2005) Redox Regulation of Histone Deacetylases and Glucocorticoid-Mediated Inhibition of the Inflammatory Response. Antioxidants & Redox Signaling 7:1-2, pages 144-152.
Crossref
Crossref
Alessandra Insinga, Silvia Monestiroli, Simona Ronzoni, Vania Gelmetti, Francesco Marchesi, Andrea Viale, Lucia Altucci, Clara Nervi, Saverio Minucci & Pier Giuseppe Pelicci. (2004) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nature Medicine 11:1, pages 71-76.
Crossref
Crossref
Claude Monneret. (2005) Histone deacetylase inhibitors. European Journal of Medicinal Chemistry 40:1, pages 1-13.
Crossref
Crossref
Paul Marks & William Kevin Kelly. 2005. DNA Methylation, Epigenetics and Metastasis. DNA Methylation, Epigenetics and Metastasis
269
305
.
Monica M. Richert & Danny R. Welch. 2005. Integration/Interaction of Oncologic Growth. Integration/Interaction of Oncologic Growth
419
435
.
Linda C. Hsi, Xiaopei Xi, Reuben Lotan, Imad Shureiqi & Scott M. Lippman. (2004) The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Induces Apoptosis via Induction of 15-Lipoxygenase-1 in Colorectal Cancer Cells. Cancer Research 64:23, pages 8778-8781.
Crossref
Crossref
K.B. Glaser, J. Li, L.J. Pease, M.J. Staver, P.A. Marcotte, J. Guo, R.R. Frey, R.B. Garland, H.R. Heyman, C.K. Wada, A. Vasudevan, M.R. Michaelides, S.K. Davidsen & M.L. Curtin. (2004) Differential protein acetylation induced by novel histone deacetylase inhibitors. Biochemical and Biophysical Research Communications 325:3, pages 683-690.
Crossref
Crossref
Seiji Doi, Hiroshi Soda, Mikio Oka, Junji Tsurutani, Takeshi Kitazaki, Yoichi Nakamura, Minoru Fukuda, Yasuaki Yamada, Shimeru Kamihira & Shigeru Kohno. (2004) The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells. Molecular Cancer Therapeutics 3:11, pages 1397-1402.
Crossref
Crossref
Tatsuo Ito, Mamoru Ouchida, Sachio Ito, Yoshimi Jitsumori, Yuki Morimoto, Toshifumi Ozaki, Akira Kawai, Hajime Inoue & Kenji Shimizu. (2004) SYT, a partner of SYT-SSX oncoprotein in synovial sarcomas, interacts with mSin3A, a component of histone deacetylase complex. Laboratory Investigation 84:11, pages 1484-1490.
Crossref
Crossref
Annemieke J.M. de Ruijter, Stephan Kemp, Gertjan Kramer, Rutger J. Meinsma, Judith O. Kaufmann, Huib N. Caron & André B.P. van Kuilenburg. (2004) The novel histone deacetylase inhibitor BL1521 inhibits proliferation and induces apoptosis in neuroblastoma cells. Biochemical Pharmacology 68:7, pages 1279-1288.
Crossref
Crossref
Kevin Camphausen, Tamalee Scott, Mary Sproull & Philip J. Tofilon. (2004) Enhancement of Xenograft Tumor Radiosensitivity by the Histone Deacetylase Inhibitor MS-275 and Correlation with Histone Hyperacetylation. Clinical Cancer Research 10:18, pages 6066-6071.
Crossref
Crossref
Steven A. Belinsky. (2004) Gene-promoter hypermethylation as a biomarker in lung cancer. Nature Reviews Cancer 4:9, pages 707-717.
Crossref
Crossref
Raphaël Margueron, Vanessa Duong, Audrey Castet & Vincent Cavaillès. (2004) Histone deacetylase inhibition and estrogen signalling in human breast cancer cells. Biochemical Pharmacology 68:6, pages 1239-1246.
Crossref
Crossref
Patrick S. Moore, Stefano Barbi, Massimo Donadelli, Chiara Costanzo, Claudio Bassi, Marta Palmieri & Aldo Scarpa. (2004) Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1693:3, pages 167-176.
Crossref
Crossref
Lynn C McGarry, Joseph N Winnie & Bradford W Ozanne. (2004) Invasion of v-FosFBR-transformed cells is dependent upon histone deacetylase activity and suppression of histone deacetylase regulated genes. Oncogene 23:31, pages 5284-5292.
Crossref
Crossref
Liwen Zhang & Michael A Freitas. (2004) Comparison of peptide mass mapping and electron capture dissociation as assays for histone posttranslational modifications. International Journal of Mass Spectrometry 234:1-3, pages 213-225.
Crossref
Crossref
Sonia C. Maggio, Roberto R. Rosato, Lora B. Kramer, Yun Dai, Mohamed Rahmani, David S. Paik, Ann C. Czarnik, Shawn G. Payne, Sarah Spiegel & Steven Grant. (2004) The Histone Deacetylase Inhibitor MS-275 Interacts Synergistically with Fludarabine to Induce Apoptosis in Human Leukemia Cells. Cancer Research 64:7, pages 2590-2600.
Crossref
Crossref
Timothy A McKinsey & Eric N Olson. (2004) Cardiac histone acetylation – therapeutic opportunities abound. Trends in Genetics 20:4, pages 206-213.
Crossref
Crossref
Junling Li, Michael J Staver, Michael L Curtin, James H Holms, Robin R Frey, Rohinton Edalji, Richard Smith, Mike R Michaelides, Steven K Davidsen & Keith B Glaser. (2004) Expression and functional characterization of recombinant human HDAC1 and HDAC3. Life Sciences 74:22, pages 2693-2705.
Crossref
Crossref
Rino RagnoAntonello MaiSilvio MassaIlaria CerbaraSergio ValentePatrizia BottoniRoberto ScatenaFlorian JesacherPeter LoidlGerald Brosch. (2004)
3-(4-Aroyl-1-methyl-1
H
-pyrrol-2-yl)-
N
-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 3. Discovery of Novel Lead Compounds through Structure-Based Drug Design and Docking Studies
,
. Journal of Medicinal Chemistry 47:6, pages 1351-1359.
Crossref
Crossref
C.-Y. Gui, L. Ngo, W. S. Xu, V. M. Richon & P. A. Marks. (2004)
Histone deacetylase (HDAC) inhibitor activation of p21
WAF1
involves changes in promoter-associated proteins, including HDAC1
. Proceedings of the National Academy of Sciences 101:5, pages 1241-1246.
Crossref
Crossref
F. Blasco, S. Peñuelas, M. Cascalló, J.L. Hernández, C. Alemany, M. Masa, J. Calbó, M. Soler, M. Nicolás, S. Pérez-Torras, A. Gómez, G. Tarrasón, V. Noé, A. Mazo, C.J. Ciudad & J. Piulats. (2004) Expression Profiles of a Human Pancreatic Cancer Cell Line upon Induction of Apoptosis Search for Modulators in Cancer Therapy. Oncology 67:3-4, pages 277-290.
Crossref
Crossref
Kevin Camphausen, William Burgan, Michael Cerra, Kelli A. Oswald, Jane B. Trepel, Min-Jung Lee & Philip J. Tofilon. (2004) Enhanced Radiation-Induced Cell Killing and Prolongation of γH2AX Foci Expression by the Histone Deacetylase Inhibitor MS-275. Cancer Research 64:1, pages 316-321.
Crossref
Crossref
William J. Meehan, Rajeev S. Samant, James E. Hopper, Michael J. Carrozza, Lalita A. Shevde, Jerry L. Workman, Kristin A. Eckert, Michael F. Verderame & Danny R. Welch. (2004) Breast Cancer Metastasis Suppressor 1 (BRMS1) Forms Complexes with Retinoblastoma-binding Protein 1 (RBP1) and the mSin3 Histone Deacetylase Complex and Represses Transcription. Journal of Biological Chemistry 279:2, pages 1562-1569.
Crossref
Crossref
Hilmar Weinmann & Eckhard Ottow. 2004.
185
196
.
Paul A. Marks, Victoria M. Richon, Thomas Miller & William Kevin Kelly. 2004.
137
168
.
Hwangseo Park & Sangyoub Lee. (2004) Homology modeling, force field design, and free energy simulation studies to optimize the activities of histone deacetylase inhibitors. Journal of Computer-Aided Molecular Design 18:6, pages 375-388.
Crossref
Crossref
Tim Shaw & Stephen Locarnini. 2004. Hepatitis Prevention and Treatment. Hepatitis Prevention and Treatment
203
238
.
R A Larson, G Q Daley, C A Schiffer, P Porcu, C-H Pui, J-P Marie, L S Steelman, F E Bertrand & J A McCubrey. (2003) Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002. Leukemia 17:12, pages 2358-2382.
Crossref
Crossref
Antonello Mai, Silvio Massa, Riccardo Pezzi, Dante Rotili, Peter Loidl & Gerald Brosch. (2003) Discovery of (Aryloxopropenyl)pyrrolyl Hydroxyamides as Selective Inhibitors of Class IIa Histone Deacetylase Homologue HD1-A. Journal of Medicinal Chemistry 46:23, pages 4826-4829.
Crossref
Crossref
Thomas A. Miller, David J. Witter & Sandro Belvedere. (2003) Histone Deacetylase Inhibitors. Journal of Medicinal Chemistry 46:24, pages 5097-5116.
Crossref
Crossref
Anil Vasudevan, Zhiqin Ji, Robin R. Frey, Carol K. Wada, Douglas Steinman, H.Robin Heyman, Yan Guo, Michael L. Curtin, Jun Guo, Junling Li, Lori Pease, Keith B. Glaser, Patrick A. Marcotte, Jennifer J. Bouska, Steven K. Davidsen & Michael R. Michaelides. (2003) Heterocyclic ketones as inhibitors of histone deacetylase. Bioorganic & Medicinal Chemistry Letters 13:22, pages 3909-3913.
Crossref
Crossref
Charlotte J. Sumner, Thanh N. Huynh, Jennifer A. Markowitz, J. Stephen Perhac, Brenna Hill, Daniel D. Coovert, Kristie Schussler, Xiaocun Chen, Jill Jarecki, Arthur H. M. Burghes, J. Paul Taylor & Kenneth H. Fischbeck. (2003) Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Annals of Neurology 54:5, pages 647-654.
Crossref
Crossref
Ricky W Johnstone & Jonathan D Licht. (2003) Histone deacetylase inhibitors in cancer therapy. Cancer Cell 4:1, pages 13-18.
Crossref
Crossref
Lalita A. Shevde & Danny R. Welch. (2003) Metastasis suppressor pathways—an evolving paradigm. Cancer Letters 198:1, pages 1-20.
Crossref
Crossref
D. R. Welch & K. W. Hunter. (2003) A New Member of the Growing Family of Metastasis Suppressors Identified in Prostate Cancer. JNCI Journal of the National Cancer Institute 95:12, pages 839-841.
Crossref
Crossref
Daniela Cecconi, Aldo Scarpa, Massimo Donadelli, Marta Palmieri, Mahmoud Hamdan, Hubert Astner & Pier Giorgio Righetti. (2003) Proteomic profiling of pancreatic ductal carcinoma cell lines treated with trichostatin‐A. ELECTROPHORESIS 24:11, pages 1871-1878.
Crossref
Crossref
Victoria M Richon, Xianbo Zhou, J.Paul Secrist, Carlos Cordon-Cardo, W.Kevin Kelly, Marija Drobnjak & Paul A Marks. 2003. Chromatin and Chromatin Remodeling Enzymes, Part B. Chromatin and Chromatin Remodeling Enzymes, Part B
199
205
.